Major Depressive Disorder & Dysthymia: Clinical Review
A Comprehensive Clinical Review of Pathophysiology, Subtypes, Differential Diagnosis, and Treatment Strategies
Major Depressive Disorder remains the leading cause of disability worldwide, affecting over 280 million individuals globally. This comprehensive review examines the evolution of depression treatment from ancient melancholia through modern neurobiological models, explores clinically relevant subtypes and differential diagnoses, and synthesizes current evidence across pharmacological and psychosocial interventionsβessential knowledge for clinicians managing this prevalent and often treatment-resistant condition.
1. Historical Evolution: From Melancholia to Modern Neuroscience
Depression has been recognized for millennia. Hippocrates (460β370 BCE) described "melancholia" as an imbalance of black bile, differentiating it from mania. This conceptualization dominated Western medicine for nearly 2,000 years, reflected in Galen's four-humors theory.
2. Depression Across Populations: Disparities, Presentations, and Diagnostic Challenges
Pediatric Depression (Ages 6β17)
- Prevalence: ~2β8% in children; ~10β15% in adolescents
- Presentation differences: Irritability more prominent than sadness; behavioral/school dysfunction often the presenting complaint
- Diagnostic challenge: Overlap with ADHD, anxiety disorders, and developmental norms; parents may minimize mood symptoms
- Treatment disparities: Underdiagnosis and undertreatment in lower-income communities; SSRIs carry FDA black-box warning for suicidality (though relative risk modest)
- Cultural factors: Some ethnic groups present depression somatically (headaches, abdominal pain); language/explanatory models vary
Adult Depression (Ages 18β64)
- Prevalence: ~5β7% annual prevalence; ~12β20% lifetime
- Work and family dysfunction: Major source of presenteeism; often drives treatment-seeking
- Racial/ethnic disparities: Black Americans show higher rates of MDD but lower treatment rates; Latino populations experience barriers including language, stigma, and immigration-related stress; Asian Americans often present with somatic symptoms
- Healthcare access: Uninsured or underinsured individuals receive later diagnoses and less specialized treatment
Geriatric Depression (Age 65+)
- Prevalence: ~10β15% in community-dwelling; up to 50% in long-term care facilities
- Presentation: Often masked as "vascular depression," cognitive complaints ("pseudodementia"), somatic preoccupation, anhedonia without sadness
- Medical comorbidity: Frequently coexists with heart disease, stroke, diabetes, cancer; bidirectional causality suspected
- Pharmacokinetic challenges: Polypharmacy, altered metabolism, increased sensitivity to anticholinergics and hyponatremia (SIADH)
- Disparities: Underdiagnosis common; attribution of mood changes to "normal aging"; racial minorities face additional barriers
3. Pathophysiology: Mechanisms and Models
The Monoamine Model
The classical monoamine hypothesis posits that depression results from deficiency of serotonin (5-HT), norepinephrine (NE), or dopamine (DA) at synaptic clefts. Evidence includes:
- All FDA-approved antidepressants increase one or more monoamine neurotransmitters
- Reserpine (depletes monoamines) induces depression
- Monoamine agonists (e.g., stimulants) show some antidepressant effect
Limitations: Monoamine reuptake blockade occurs within hours, yet clinical improvement takes weeks; ~30β40% of patients are treatment-resistant despite adequate monoamine elevation.
Neuroinflammation and Cytokine Models
Emerging evidence demonstrates elevated pro-inflammatory cytokines (IL-6, TNF-Ξ±, IL-1Ξ²) in ~30% of depressed patients. Proposed mechanisms:
- Microglia activation: Stress and trauma activate brain resident immune cells, releasing inflammatory mediators
- Blood-brain barrier dysfunction: Allows peripheral immune activation to reach brain
- Reduced trophic support: Inflammation suppresses BDNF and neurogenesis
This subtype may explain poor SSRI response and the rationale for anti-inflammatory augmentation (NSAIDs, curcumin, omega-3s) or IL-6 antagonists in trials.
HPA-Axis Dysfunction
Depression involves dysregulation of the hypothalamic-pituitary-adrenal axis, resulting in:
- Elevated cortisol: Especially in melancholic depression; dexamethasone suppression test (DST) may show non-suppression
- CRH hypersecretion: Central driver of HPA hyperactivity
- Glucocorticoid receptor dysfunction: Impaired negative feedback
- Downstream effects: Hippocampal atrophy, impaired neurogenesis, metabolic derangement
Neuroplasticity and Neurotrophic Factors
Depression is characterized by reduced brain-derived neurotrophic factor (BDNF), especially in the hippocampus and prefrontal cortex. This leads to:
- Impaired neurogenesis in the dentate gyrus
- Dendritic atrophy and reduced synaptic density
- Diminished cognitive function (memory, executive function)
- All antidepressants, psychotherapy, and exercise increase BDNF and promote neuroplasticity
Gut-Brain Axis and Microbiota
The gut microbiota influences mood through:
- SCFA production: Microbial fermentation produces short-chain fatty acids (butyrate, propionate) that cross the BBB and enhance GABA signaling
- Tryptophan metabolism: Dysbiosis reduces tryptophan conversion to kynurenine and serotonin precursors
- Lipopolysaccharide (LPS): Dysbiosis permits gram-negative bacterial endotoxin translocation, triggering systemic inflammation
- Vagal afferents: Microbiota-derived signals reach the brain via the vagus nerve
4. Clinical Subtypes of Depression: Diagnostic Distinctions and Treatment Implications
| Subtype | Core Features | Prevalence in MDD | Treatment Pearls |
|---|---|---|---|
| Major Depressive Disorder (MDD) | β₯5 symptoms for β₯2 weeks; functional impairment; mood/anhedonia essential | Baselineβ100% | Treat as per algorithm; most responsive to SSRIs/SNRIs |
| Persistent Depressive Disorder (Dysthymia) | β₯3 symptoms for β₯2 years (children β₯1 year); no >2-month break; lower severity | ~3% lifetime; often comorbid with MDD ("double depression") | Longer trials needed; augmentation or combination therapy often required |
| Melancholic Depression | Loss of pleasure/interest, guilt, morning worsening, early awakening, psychomotor changes, significant appetite loss, anhedonia | ~30% of MDD | More responsive to tricyclics and venlafaxine; ECT highly effective; sleep deprivation paradoxically helpful |
| Atypical Depression | Mood reactivity (mood brightens with positive events), hyperphagia, hypersomnia, leaden paralysis, rejection sensitivity | ~20% of MDD | SSRIs generally effective; MAOIs historically superior; avoid tricyclics (poor response) |
| Psychotic Depression | MDD + mood-congruent delusions or hallucinations (guilt, poverty, somatic concerns, nihility) | ~15% of MDD hospitalized | Requires antipsychotic + antidepressant; ECT highly effective; augmentation monotherapy poor |
| Catatonic Depression | MDD + catatonic features (waxy flexibility, mutism, negativism, echolalia, stupor) | Rare (~0.5% MDD) | Lorazepam challenge diagnostic and therapeutic; ECT first-line |
| Peripartum Depression | MDD onset during pregnancy or β€4 weeks postpartum | ~10β15% of pregnancies | SSRIs safe in pregnancy (risks must be weighed vs. untreated depression); consider lactation when selecting agent |
| Seasonal Affective Disorder (SAD) | MDD with temporal pattern (onset in fall/winter); remission spring/summer | ~5% in temperate climates | Light therapy 10,000 lux Γ 30 min/day highly effective; SSRIs/SNRIs; bupropion; vitamin D debate ongoing |
Persistent Depressive Disorder (Dysthymia)
Diagnostic criteria: Depressed mood for most days for β₯2 years (β₯1 year in children/adolescents); β₯2 additional symptoms (poor appetite, hypersomnia/insomnia, low energy, low self-worth, poor concentration, hopelessness); never without symptoms for >2 months; functional impairment but usually mild to moderate.
Key distinctions from MDD: Dysthymia is chronic but less severe; two-thirds of dysthymia patients experience superimposed MDD episodes ("double depression"). Treatment-resistance is common in dysthymia alone; combination pharmacotherapy or augmentation more frequently needed.
Depression Severity Spectrum and Subtypes
5. Critical Differential Diagnoses Not to Miss
Misattributing secondary causes of depression to primary MDD delays treatment and may miss treatable underlying pathology.
Medical Etiologies
Hypothyroidism
Presentation: Depression + fatigue, weight gain, cold intolerance, bradycardia, myxedema.
Mechanism: Thyroid hormone essential for monoamine synthesis and receptor expression.
Red flags: Female, age >40, family history. Obtain TSH and free T4.
Vitamin B12 Deficiency
Presentation: Depression, cognitive impairment, paresthesias, macrocytic anemia, ataxia.
Mechanism: B12 required for myelin formation and monoamine synthesis.
Red flags: Pernicious anemia, veganism, GI surgery. Check serum B12, methylmalonic acid, homocysteine.
Folate Deficiency
Presentation: Depression, cognitive dysfunction, macrocytic anemia.
Mechanism: Folate cofactor in methylation reactions; low serum folate correlates with poor antidepressant response.
Red flags: Poor diet, alcohol use, malabsorption. Low serum folate, elevated homocysteine predicts poor SSRI response.
Obstructive Sleep Apnea
Presentation: Depression, daytime somnolence, witnessed apneas, hypertension.
Mechanism: Sleep fragmentation β HPA hyperactivity, reduced BDNF, monoamine dysregulation.
Red flags: Loud snoring, BMI >30, witnessed apnea. Screen with STOP-BANG; refer for sleep study.
Substance-Induced and Medication-Induced Depression
- Alcohol: Chronic use depresses CNS; withdrawal hyperexcitability. "Dry drunk" syndrome may mimic depression.
- Stimulant use/withdrawal: Cocaine, methamphetamine cause depression upon cessation or chronic use.
- Beta-blockers: Propranolol, atenolol associated with depression (especially at higher doses); mechanism unclear.
- Corticosteroids: Prednisone, dexamethasone (especially >20 mg/day) induce mood disturbance; mood improves with taper.
- Interferon-Ξ±: Directly induces depression in ~30% of patients; IFN-Ξ³ pathway implicated.
- Isotretinoin: Acne medication linked to depression and suicidality; mechanism unknown.
Bipolar Depression and Diagnostic Dilemma
Patients with unrecognized bipolar disorder receiving antidepressant monotherapy risk mood destabilization, rapid cycling, and treatment resistance.
- Screening: Mood Disorder Questionnaire (MDQ), lifetime history of elevated/expansive mood, decreased need for sleep, racing thoughts, excessive spending, or risky behavior
- Key history: Ask about family history of mania, hypomanic responses to antidepressants, or antidepressant-induced rapid cycling
- Treatment difference: Bipolar depression requires mood stabilizer Β± antidepressant, not antidepressant monotherapy
Early Dementia and Pseudodementia
Pseudodementia: Depression mimicking cognitive decline. Depressed patients show poor effort on cognitive testing, subjective memory complaints exceeding objective deficits, rapid onset, and mood precedes cognitive symptoms.
True dementia: Cognitive decline precedes mood symptoms; objective deficits on testing; insidious onset; antidepressants don't normalize cognition (though may improve mood).
Red flag: Geriatric depression with new cognitive complaints warrants careful cognitive assessment to exclude early Alzheimer's, vascular dementia, or Lewy body disease.
6. Pharmacological Treatment of Depression: Agents, Mechanisms, and Evidence
Treatment Algorithm: Sequencing by Severity
First-Generation Antidepressants: Tricyclic Antidepressants (TCAs)
Mechanism
Block reuptake of NE and 5-HT; anticholinergic, antihistamine, and alpha-blocking properties.
Efficacy
Equivalent to SSRIs; superior in melancholic depression; poor response in atypical depression.
Agents & Dosing
Amitriptyline: 50β300 mg/day
Nortriptyline: 50β150 mg/day (narrower therapeutic window)
Imipramine, Doxepin
Adverse Effects
Anticholinergic (dry mouth, urinary retention, constipation), orthostasis, weight gain, sexual dysfunction, cardiac conduction delay (ECG needed >60 yo).
Clinical use today: Largely superseded by SSRIs due to side effect burden and overdose risk, but valuable in melancholic depression, neuropathic pain, migraine prophylaxis, and nocturia.
Second-Generation: SSRIs and SNRIs
| Agent | Mechanism | Typical Dose | Key Advantages | Key Drawbacks |
|---|---|---|---|---|
| Sertraline (SSRI) | 5-HT reuptake inhibition | 50β200 mg/day | First-line; minimal metabolism; safe in hepatic disease; low drug interactions | GI upset, sexual dysfunction, apathy |
| Escitalopram (SSRI) | 5-HT reuptake inhibition | 10β20 mg/day | Highly selective; rapid onset; good tolerability | QTc prolongation at doses >20 mg/day; sexual dysfunction |
| Paroxetine (SSRI) | 5-HT reuptake inhibition | 20β60 mg/day | Effective; anticholinergic (may help anxiety/sleep) | High discontinuation syndrome; weight gain; sexual dysfunction |
| Venlafaxine (SNRI) | 5-HT + NE reuptake inhibition | 75β375 mg/day | Dose-dependent: <150 mg 5-HT; β₯150 mg dual action; effective in melancholic, TRD | Hypertension, sexual dysfunction, discontinuation syndrome |
| Duloxetine (SNRI) | 5-HT + NE reuptake inhibition | 60β120 mg/day | Also effective for chronic pain, anxiety; good tolerability at lower doses | Hypertension, sexual dysfunction, nausea |
Novel Agents
Bupropion (Dopamine/NE Reuptake Inhibitor)
Unique features: Activating; no sexual dysfunction; weight loss; may elevate seizure risk (dose-dependent; contraindicated if seizure disorder).
Use: Apathetic/withdrawn depression; augmentation with SSRIs; smoking cessation; comorbid ADHD. Dose: 300β450 mg/day.
Mirtazapine (Noradrenergic + 5-HT Antagonist)
Unique features: Sedating; increases appetite; dual mechanism at alpha-2 and 5-HT receptors.
Use: Depression with insomnia, anorexia; anxiety comorbidity. Dose: 15β45 mg/day (often given qhs).
Monoamine Oxidase Inhibitors (MAOIs)
Mechanism: Irreversibly inhibit monoamine oxidase enzymes A and B, preventing neurotransmitter degradation. Phenelzine and tranylcypromine are irreversible; moclobemide is reversible.
Efficacy: Superior to SSRIs in atypical depression; particularly effective for depression with rejection sensitivity and hypersomnia; may also help in panic, OCD, PTSD.
Adverse effects: Hypertensive crisis (tyramine-containing foods: aged cheese, cured meats, fermented sauces), orthostasis, weight gain, insomnia, sexual dysfunction. Require strict dietary adherence.
Use: Second/third-line due to complexity and MAOI-SSRI serotonin syndrome risk, but valuable in treatment-resistant atypical depression. Phenelzine 45β90 mg/day; tranylcypromine 20β60 mg/day.
Augmentation Strategies for Treatment-Resistant Depression
Treatment-resistant depression (TRD) is defined as failure to achieve remission after β₯2 adequate trials (β₯8 weeks at therapeutic dose) of antidepressants. Affects ~30% of depressed patients.
Approximate response rates for augmentation in TRD (adapted from meta-analyses).
Lithium
- Efficacy: ~50β60% response/remission rate; strongest evidence; takes 1β2 weeks to see benefit
- Mechanism: Enhances 5-HT function; promotes BDNF and neurogenesis; potentiates monoamine effects
- Dosing: 600β1,200 mg/day; therapeutic level 0.6β1.2 mEq/L
- Monitoring: Baseline renal function, TSH; repeat annually. Assess sodium intake, dehydration, drug interactions (NSAIDs, ACE-inhibitors, thiazides elevate lithium)
- Toxicity: Narrow therapeutic index; tremor, polyuria, hypothyroidism, renal impairment with chronic use
Atypical Antipsychotics
- Efficacy: ~50β55% response; aripiprazole, quetiapine, olanzapine FDA-approved for augmentation
- Mechanism: D2 dopamine blockade + 5-HT2A antagonism; enhance monoamine signaling
- Dosing: Lower than psychosis doses (aripiprazole 2β5 mg/day, quetiapine 25β100 mg/day at bedtime)
- Drawback: Weight gain, metabolic effects (even at low doses), akathisia, tardive dyskinesia risk (though lower at antidepressant augmentation doses)
Thyroid Hormone (T3/Triiodothyronine)
- Efficacy: ~50% response when added to TCAs; less robust with SSRIs; mechanism unclear
- Dosing: 25β50 mcg/day; total dose 25β100 mcg/day
- Mechanism: May enhance monoamine synthesis, BDNF, and neuroplasticity; synergizes with antidepressants
- Note: Beneficial even in euthyroid patients; doesn't require TSH elevation to work
Rapid-Acting Interventions for Severe and Treatment-Resistant Depression
Ketamine and Esketamine (Rapid-Acting Glutamatergic Agents)
- Mechanism: NMDA receptor antagonism; rapid AMPA receptor potentiation; increases BDNF and promotes synaptogenesis within hours
- Efficacy: 50β70% response in TRD; onset 24 hours to 1 week (much faster than conventional antidepressants)
- Formulations: IV ketamine (0.5β1 mg/kg Γ 40 min; weekly infusions); intranasal esketamine (Spravato: 56β84 mg twice weekly initially)
- Clinical use: Especially valuable in acute suicidal crisis; rapid mood improvement; used in inpatient and office settings
- Limitations: Dissociation during infusion; abuse potential (ketamine); expensive; esketamine requires supervised administration; long-term efficacy data limited
Transcranial Magnetic Stimulation (TMS)
- Mechanism: Repetitive TMS (rTMS) induces localized brain stimulation (dorsolateral prefrontal cortex); enhances monoamine function and promotes plasticity
- Efficacy: ~40β50% response in TRD; remission ~20β30%; comparable to augmentation; noninvasive
- Schedule: Typically 5 sessions/week Γ 4β6 weeks; maintenance protocols available
- Advantages: No systemic side effects; cognitive benefit (vs. ECT); no seizure risk; portable devices emerging for home use
- Limitations: Modest efficacy; time commitment; scalp discomfort; cost
Electroconvulsive Therapy (ECT)
- Mechanism: Generalized seizure induction under anesthesia; promotes neuroplasticity and potentiates monoamine signaling; most powerful antidepressant known
- Efficacy: ~60β80% response; ~50% remission, especially in psychotic, melancholic, and catatonic depression; faster than medication (days to weeks)
- Indications: Psychotic depression, catatonia, melancholic depression with profound symptoms, high suicidality, need for rapid response, medication intolerance, prior ECT response
- Administration: Anesthetic, muscle relaxant, and ECT device; bilateral or unilateral electrode placement (unilateral has fewer cognitive effects but less efficacy)
- Adverse effects: Post-ictal confusion, transient cognitive impairment (usually fully reversible); headache, muscle ache
- Maintenance: Maintenance ECT (once weekly to monthly) improves sustained remission; often continued antidepressant therapy
Vagus Nerve Stimulation (VNS)
- Mechanism: Surgical implantation of electrode on vagus nerve; electrical stimulation β increased vagal signaling to brain β monoamine and BDNF enhancement
- Efficacy: ~25β35% response in TRD; slow onset (6β12 months); FDA-approved for TRD
- Advantages: Durable; reversible; relatively safe; improves over time
- Limitations: Invasive surgery required; modest efficacy; cost; slow onset
Psilocybin and Classical Psychedelics
- Status: Phase 2b/3 clinical trials ongoing; preliminary data promising; FDA breakthrough therapy designation for psilocybin-assisted therapy (COMP360 program)
- Mechanism: Serotonin 2A receptor agonism; increased neuroplasticity; possible "resetting" of rigid depressive thought patterns via dissociation and psychological insight
- Efficacy: ~50β70% response in early trials; sustained benefit at 6 months post-treatment in some studies
- Setting: Administered with psychological support/therapy ("set and setting"); not simple pill therapy
- Timeline: Likely approved 2025β2027 for clinical use; currently research only
7. Non-Pharmacological Treatments: Evidence and Efficacy
Psychotherapy and behavioral interventions are first-line for mild-to-moderate depression and essential adjuncts to medication in severe depression.
Challenge automatic thoughts and modify behavior; typically 12β16 sessions. Response 50β60%; comparable to SSRI monotherapy.
Address interpersonal conflict, role transitions, grief, and social deficits; typically 16 sessions. Response 60%; especially effective for role-related depression.
Systematic engagement in valued activities; counters avoidance. Simple, brief (8β12 sessions); response 60β70% for mild-moderate depression.
Combines mindfulness meditation and CBT; originally for recurrence prevention. Response 50β60%; especially for rumination and relapse prevention.
Address unconscious conflicts and patterns. Response 50β60%; may take longer (20+ sessions) but durable gains. Effective for complex trauma-related depression.
10,000 lux exposure Γ 30 min morning. First-line for seasonal depression; response 70β80%. Also studied in non-seasonal depression and bipolar.
Behavioral and Lifestyle Interventions
Exercise
- Efficacy: 30 min aerobic activity 5Γ weekly equivalent to SSRI; dose-response relationship
- Mechanism: Increases BDNF, serotonin, endorphins; improves HPA function; sleep benefit
- Evidence: Meta-analyses show moderate-to-large effect sizes; recommended as first-line or adjunct
Sleep Hygiene and Sleep Deprivation
- Sleep restriction: Sleep deprivation induces rapid mood improvement in ~60% of depressed patients (paradoxically); effect typically wanes after one night of recovery sleep
- Chronotherapy: Sleep phase advance (earlier bedtime) or circadian rhythm alignment helps especially in seasonal depression
- Insomnia treatment: Cognitive-behavioral therapy for insomnia (CBT-I) as adjunct; untreated sleep apnea worsens depression outcomes
Social Rhythm Therapy and Interpersonal and Social Rhythm Therapy (IPSRT)
- Mechanism: Regular sleep-wake schedule, meal times, social activities stabilize mood and circadian function
- Evidence: Effective as maintenance therapy; particularly beneficial in bipolar depression and seasonal patterns
Nutritional Approaches
- Omega-3 fatty acids: Mixed evidence; some benefit in moderate depression; >2 g EPA+DHA daily potentially adjunctive
- Folic acid and B vitamins: Deficiency associated with poor treatment response; supplementation reasonable, especially if low baseline levels
- Gut-directed interventions: Probiotics, prebiotics, fiber show preliminary benefit in depression (through microbiota modification); emerging area
Meditation and Mindfulness
- Mindfulness-Based Cognitive Therapy (MBCT): 50β60% response; effective for rumination and recurrence prevention
- Mechanism: Reduces engagement with depressive thoughts; activates anterior cingulate and prefrontal cortex
8. Clinical Management Overview and Key Takeaways
Initial Assessment Checklist
- Structured diagnostic interview (PHQ-9, HAM-D); confirm β₯5 symptoms Γ β₯2 weeks
- Assess severity: suicidality, psychosis, catatonia, functional impairment
- Rule out bipolar spectrum (MDQ, personal/family hx of mania)
- Screen for secondary causes: TSH, B12, folate, CBC, substance use, medications, sleep apnea (STOP-BANG)
- Assess past response and tolerability to antidepressants
- Evaluate comorbidities (anxiety, PTSD, substance use, medical conditions)
- Document baseline weight, metabolic parameters, EKG if >60 yo or cardiac risk
Treatment Selection by Severity
- Mild: Psychotherapy, exercise, or SSRI monotherapy; watchful waiting acceptable with strong social support
- Moderate: SSRI/SNRI + psychotherapy (combined most effective); venlafaxine for melancholic features
- Severe with psychosis: SSRI + atypical antipsychotic; ECT urgently if suicidal or catatonic
- Severe with suicidality: Hospitalization if imminent risk; ketamine, ECT, or intensive outpatient program (IOP)
Monitoring During Antidepressant Trial
- Week 1β2: Check for adverse effects, activation, behavioral changes, suicidality (especially youth)
- Week 4: First efficacy assessment; expect modest improvement (PHQ-9 decrease of 2β3 points)
- Week 8β12: Major reassessment; if β₯50% response, continue to 12β16 weeks for full remission attempt
- Partial response: Consider dose increase, switch, or augmentation strategy
- No response: Verify adherence, adequate dosing/duration, lack of substance use; change strategy by week 12
Maintenance and Relapse Prevention
- Duration: Continue antidepressant β₯6β12 months after remission for first episode; consider indefinite for recurrent depression (β₯3 episodes or 2 if severe)
- Psychotherapy: Maintenance CBT, IPT, or MBCT reduces relapse ~20β30%
- Lifestyle: Exercise, regular sleep-wake schedule, social connection, stress management
- Discontinuation: Gradual taper (10% reduction per 1β2 weeks) to avoid discontinuation syndrome
References
- American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095β3105.
- Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34(1):13β25.
- Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299β2312.
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28β40.
- Jakubovski E, Bloch MH. Augmentation strategies for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2018;79(5):17r11960.
- Howland RH. Neurotransmitter hypothesis of depression. J Clin Psychiatry. 2010;71(4):e14.
- Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29(6):417β426.
- Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446β457.
- Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 2012;35(1):1β17.
- Ionescu DF, Papakostas GI. Ethnicity and antidepressant response. Curr Psychiatry Rep. 2013;15(11):413.
- Holtzheimer PE, Mayberg HS. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci. 2011;34(1):1β9.
- Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894β902.
- Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2015;78(8):e29βe30.
- Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065.
- Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine and imipramine in mood reactive depressives. Arch Gen Psychiatry. 1989;46(9):787β793.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905β1917.
- Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399β405.
- Thomson F, Frick L. Prospects for the development of rapid-acting antidepressants. Curr Neuropharmacol. 2012;10(1):17β25.
- WHO. (2021). World Mental Health Report: Transforming Mental Health for All. Geneva: World Health Organization.
- Yeung AS, Feldman G, Fava M. Self-reported dietary factors and Five-HTTLPR genotype in relation to depression severity in Asian Americans. J Affect Disord. 2011;129(1β3):156β161.
- Zajecka JM. Safety of antidepressants in pregnancy and lactation. Psychiatr Clin North Am. 2013;36(1):75β90.
- Lopresti AL, Hood SD, Drummond PD. Multiple antidepressants and side-effects: a narrative review. Drugs Context. 2018;7:212551.
- Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045β1055.
- Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(6):e04.